NASDAQ:AMRN

Amarin Competitors

$5.02
+0.01 (+0.20 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.86
Now: $5.02
$5.07
50-Day Range
$5.01
MA: $6.18
$6.95
52-Week Range
$3.36
Now: $5.02
$9.25
Volume4.41 million shs
Average Volume6.89 million shs
Market Capitalization$1.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.58

Competitors

Amarin (NASDAQ:AMRN) Vs. RARE, ARWR, GWPH, ASND, TGTX, and IONS

Should you be buying AMRN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Amarin, including Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

Amarin (NASDAQ:AMRN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

37.8% of Amarin shares are held by institutional investors. 2.8% of Amarin shares are held by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amarin and Ultragenyx Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin03802.73
Ultragenyx Pharmaceutical06802.57

Amarin presently has a consensus target price of $11.1818, suggesting a potential upside of 122.75%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, suggesting a potential upside of 20.68%. Given Amarin's stronger consensus rating and higher possible upside, equities analysts clearly believe Amarin is more favorable than Ultragenyx Pharmaceutical.

Risk & Volatility

Amarin has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares Amarin and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-2.69%-2.70%-1.72%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Earnings & Valuation

This table compares Amarin and Ultragenyx Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million4.60$-22,650,000.00($0.07)-71.71
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77

Amarin has higher revenue and earnings than Ultragenyx Pharmaceutical. Amarin is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Amarin beats Ultragenyx Pharmaceutical on 10 of the 13 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Amarin and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-2.69%-2.70%-1.72%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Earnings & Valuation

This table compares Amarin and Arrowhead Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million4.60$-22,650,000.00($0.07)-71.71
Arrowhead Pharmaceuticals$87.99 million79.80$-84,550,000.00($0.84)-80.54

Amarin has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amarin has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Institutional & Insider Ownership

37.8% of Amarin shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 2.8% of Amarin shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amarin and Arrowhead Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin03802.73
Arrowhead Pharmaceuticals021002.83

Amarin presently has a consensus target price of $11.1818, suggesting a potential upside of 122.75%. Arrowhead Pharmaceuticals has a consensus target price of $85.3077, suggesting a potential upside of 26.10%. Given Amarin's higher possible upside, equities analysts clearly believe Amarin is more favorable than Arrowhead Pharmaceuticals.

Summary

Amarin beats Arrowhead Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Amarin and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-2.69%-2.70%-1.72%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Valuation & Earnings

This table compares Amarin and GW Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million4.60$-22,650,000.00($0.07)-71.71
GW Pharmaceuticals$311.33 million22.04$-9,020,000.00($0.24)-912.08

GW Pharmaceuticals has lower revenue, but higher earnings than Amarin. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amarin has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500.

Institutional and Insider Ownership

37.8% of Amarin shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amarin and GW Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin03802.73
GW Pharmaceuticals010402.29

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. GW Pharmaceuticals has a consensus price target of $204.0909, suggesting a potential downside of 6.77%. Given Amarin's stronger consensus rating and higher possible upside, research analysts plainly believe Amarin is more favorable than GW Pharmaceuticals.

Summary

Amarin beats GW Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Amarin and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-2.69%-2.70%-1.72%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Valuation & Earnings

This table compares Amarin and Ascendis Pharma A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million4.60$-22,650,000.00($0.07)-71.71
Ascendis Pharma A/S$14.98 million437.57$-244,180,000.00($5.25)-23.23

Amarin has higher revenue and earnings than Ascendis Pharma A/S. Amarin is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amarin has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Institutional and Insider Ownership

37.8% of Amarin shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amarin and Ascendis Pharma A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin03802.73
Ascendis Pharma A/S011102.92

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. Ascendis Pharma A/S has a consensus price target of $187.6667, suggesting a potential upside of 53.89%. Given Amarin's higher possible upside, research analysts plainly believe Amarin is more favorable than Ascendis Pharma A/S.

Summary

Amarin beats Ascendis Pharma A/S on 9 of the 14 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Amarin and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-2.69%-2.70%-1.72%
TG Therapeutics-151,798.69%-223.96%-108.08%

Valuation & Earnings

This table compares Amarin and TG Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million4.60$-22,650,000.00($0.07)-71.71
TG Therapeutics$150,000.0041,969.61$-172,870,000.00($1.83)-24.47

Amarin has higher revenue and earnings than TG Therapeutics. Amarin is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amarin has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Institutional and Insider Ownership

37.8% of Amarin shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amarin and TG Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin03802.73
TG Therapeutics00503.00

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 42.92%. Given Amarin's higher possible upside, research analysts plainly believe Amarin is more favorable than TG Therapeutics.

Summary

Amarin beats TG Therapeutics on 9 of the 14 factors compared between the two stocks.

Amarin (NASDAQ:AMRN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Institutional and Insider Ownership

37.8% of Amarin shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amarin and Ionis Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amarin03802.73
Ionis Pharmaceuticals27602.27

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 42.00%. Given Amarin's stronger consensus rating and higher possible upside, research analysts plainly believe Amarin is more favorable than Ionis Pharmaceuticals.

Valuation & Earnings

This table compares Amarin and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$429.76 million4.60$-22,650,000.00($0.07)-71.71
Ionis Pharmaceuticals$1.12 billion5.12$303.26 million$2.0819.61

Ionis Pharmaceuticals has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amarin and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amarin-2.69%-2.70%-1.72%
Ionis Pharmaceuticals7.82%6.57%3.39%

Volatility & Risk

Amarin has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Summary

Ionis Pharmaceuticals beats Amarin on 9 of the 14 factors compared between the two stocks.


Amarin Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72+0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65+0.5%$7.02 billion$87.99 million-80.54News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90+0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95+1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78+2.3%$6.30 billion$150,000.00-21.12High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78+0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80+1.2%$5.70 billion$380.83 million-9.18Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.3$41.62+1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50+3.5%$5.55 billionN/A-38.14Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20+0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$77.90+0.6%$5.45 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15+0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40+1.9%$4.62 billionN/A-6.06Analyst Revision
Gap Down
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64+1.2%$4.36 billion$6.87 million-7.21Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25+0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96Analyst Report
Gap Up
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+3.2%$3.98 billion$806.43 million-9.33Analyst Report
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69+0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94+2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57+1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03+5.8%$3.58 billionN/A-20.81Analyst Report
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00+1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00+0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59+0.8%$3.42 billion$306.98 million-6.95News Coverage
Insmed logo
INSM
Insmed
1.2$33.07+1.7%$3.42 billion$136.47 million-12.72News Coverage
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15+0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87+1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54+1.3%$3.25 billion$36.13 million-69.46News Coverage
Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.87+0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69+2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60+4.2%$3.04 billionN/A-56.02Insider Selling
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.65+2.3%$2.98 billion$80.43 million107.86Decrease in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.34+0.5%$2.91 billion$901.90 million-24.11Gap Up
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64+1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07+5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46+5.3%$2.75 billion$260.98 million-357.67Analyst Downgrade
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00+0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39+0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77+0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94+3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Gap Down
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81+1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22+3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23+0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26+5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73+0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57+2.6%$2.35 billion$33.94 million-88.91Gap Down
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13+5.6%$2.35 billion$15 million-17.35Unusual Options Activity
News Coverage
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22+0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96+1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.